Loading...
Loading...
In a report published Tuesday, Morgan Stanley analyst Ricky R. Goldwasser initiated coverage on Quintiles Transnational Q with an Overweight rating and $51.00 price target.
In the report, Morgan Stanley noted, “As the contract research organization (CRO) market leader with 11% share of clinical outsourcing, a diversified customer base and backlog visibility, we believe Quintiles is best positioned to benefit from the growth in biopharmaceutical R&D outsourcing.”
Quintiles Transnational closed on Monday at $43.53.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in